Avenue Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Avenue Therapeutics generated cash of -$9,451,000, which is less than the previous year. Cash used in financing activities reached the amount of $7,526,000 last year. Net change in cash is therefore -$4,925,000.
Cash Flow
| 2015 | -895K | -3M | 3.90M |
|---|---|---|---|
| 2016 | -1.63M | 0 | 1.81M |
| 2017 | -6.80M | -10M | 28.38M |
| 2018 | -18.21M | 10M | -895K |
| 2019 | -26.25M | 0 | 32.33M |
| 2020 | -4.61M | -1M | 0 |
| 2021 | -3.75M | 0 | 4.38M |
| 2022 | -7.59M | 0 | 10.54M |
| 2023 | -9.45M | -3M | 7.52M |
ATXI Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.70M | 3.76M | 3.13M | 8.74M | 2.67M | 11.78M | 197K | 14K | 0 |
Operating activities | |||||||||
Net income | -10.37M | -3.60M | -3.73M | -5.15M | -25.90M | -21.54M | -12.25M | -3.17M | -5.22M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 174K | 0 | 0 |
Stock-based compensation expense | 906K | 649K | 442K | 710K | 1.83M | 0 | 604K | 28K | 55 |
| Deferred income tax benefit | 906K | 649K | 442K | 710K | 1.83M | 0 | 604K | 28K | 55 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 90K | -90K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | -90K | 90K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -360K | 385K | -406K | -229K | -3.23M | 1.12M | 2.23M | 15K | 0 |
Cash generated by operating activities | -9.45M | -7.59M | -3.75M | -4.61M | -26.25M | -18.21M | -6.80M | -1.63M | -895K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -5M | 10M | -10M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -1M | 0 | 0 | 0 | 0 | -3M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3M | 0 | 0 | -1M | 0 | 10M | -10M | 0 | -3M |
Financing activities | |||||||||
Common Stock Issued | 7.52M | 11.49M | 5.04M | 0 | 35M | 0 | 37.95M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -1.10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -3M | 0 | 3.90M |
Cash used in financing activities | 7.52M | 10.54M | 4.38M | 0 | 32.33M | -895K | 28.38M | 1.81M | 3.90M |
Net Change In Cash | -4.92M | 2.94M | 631K | -5.61M | 6.07M | -9.11M | 11.58M | 183K | 14K |
Cash at end of period | 1.78M | 6.70M | 3.76M | 3.13M | 8.74M | 2.67M | 11.78M | 197K | 14K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |